Can we define difficult-to-treat systemic sclerosis?

References

• Nagy G, Roodenrijs NMT, Welsing PM, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80(1):31–35. doi: 10.1136/annrheumdis-2020-217344
   PubMed Web of Science ®Google Scholar
• Nagy G, Roodenrijs NMT, Welsing PMJ, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2022;81(1):20–33. doi: 10.1136/annrheumdis-2021-220973
   PubMed Web of Science ®Google Scholar
• Wendling D, Verhoeven F, Prati C. Is the difficult-to-treat (D2T) concept applicable to axial spondyloarthritis? Joint Bone Spine. 2023;90(3):105512. doi: 10.1016/j.jbspin.2022.105512
   PubMed Web of Science ®Google Scholar
• Kumthekar A, Ashrafi M, Deodhar A. Difficult to treat psoriatic arthritis - how should we manage? Clin Rheumatol. 2023;42(9):2251–2265. doi: 10.1007/s10067-023-06605-9
   PubMed Web of Science ®Google Scholar
• Maffi M, Tani C, Cascarano G, et al. Which extra-renal flare is ‘difficult to treat’ in systemic lupus erythematosus? A one-year longitudinal study comparing traditional and machine learning approaches. Rheumatology (Oxford). 2023;63(2):376–384. doi: 10.1093/rheumatology/kead166
   Web of Science ®Google Scholar
• Dereme J, Belkoniene M, Ribi C. Difficult to treat auto-immune diseases: when glucocorticoids are not enough. Rev Med Suisse. 2022;18(764–5):15–17. doi: 10.53738/REVMED.2022.18.764-65.15
   PubMedGoogle Scholar
• Truchetet ME, Brembilla NC, Chizzolini C. Current concepts on the pathogenesis of systemic sclerosis. Clin Rev Allergy Immunol. 2023;64(3):262–283. doi: 10.1007/s12016-021-08889-8
   PubMed Web of Science ®Google Scholar
• Nagaraja V, Matucci-Cerinic M, Furst DE, et al. Current and future outlook on disease modification and defining low disease activity in systemic sclerosis. Arthritis Rheumatol. 2020;72(7):1049–1058. doi: 10.1002/art.41246
   PubMed Web of Science ®Google Scholar
• Ko J, Noviani M, Chellamuthu VR, et al. The pathogenesis of systemic sclerosis: the origin of fibrosis and interlink with Vasculopathy and autoimmunity. Int J Mol Sci. 2023;24(18):14287. doi: 10.3390/ijms241814287
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, McInnes IB, Schett G, et al. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17(10):585–595. doi: 10.1038/s41584-021-00652-9
   PubMed Web of Science ®Google Scholar
• Humby F, Durez P, Buch MH, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021;397(10271):305–317. doi: 10.1016/S0140-6736(20)32341-2
   PubMed Web of Science ®Google Scholar
• Milano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLOS ONE. 2008;3(7):e2696. doi: 10.1371/journal.pone.0002696
   PubMed Web of Science ®Google Scholar
• Pendergrass SA, Lemaire R, Francis IP, et al. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol. 2012;132(5):1363–1373. doi: 10.1038/jid.2011.472
   PubMed Web of Science ®Google Scholar
• Taroni JN, Greene CS, Martyanov V, et al. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Med. 2017;9(1):27. doi: 10.1186/s13073-017-0417-1
   PubMedGoogle Scholar
• Assassi S, Swindell WR, Wu M, et al. Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis. Arthritis Rheumatol. 2015;67(11):3016–3026. doi: 10.1002/art.39289
   PubMed Web of Science ®Google Scholar
• Skaug B, Khanna D, Swindell WR, et al. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann Rheum Dis. 2020;79(3):379–386. doi: 10.1136/annrheumdis-2019-215894
   PubMed Web of Science ®Google Scholar
• Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76(11):1897–1905. doi: 10.1136/annrheumdis-2017-211448
   PubMed Web of Science ®Google Scholar
• Dai B, Ding L, Zhao L, et al. Contributions of immune cells and stromal cells to the pathogenesis of systemic sclerosis: recent insights. Front Pharmacol. 2022;13:826839. doi: 10.3389/fphar.2022.826839
   PubMed Web of Science ®Google Scholar
• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–1699. doi: 10.1016/S0140-6736(17)30933-9
   PubMed Web of Science ®Google Scholar
• Salazar GA, Assassi S, Wigley F, et al. Antinuclear antibody-negative systemic sclerosis. Semin Arthritis Rheum. 2015;44(6):680–686. doi: 10.1016/j.semarthrit.2014.11.006
   PubMed Web of Science ®Google Scholar
• Sobanski V, Giovannelli J, Lynch BM, et al. Characteristics and survival of anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol. 2016;68(2):484–493. doi: 10.1002/art.39432
   PubMed Web of Science ®Google Scholar
• Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM. 2007;100(8):485–494. doi: 10.1093/qjmed/hcm052
   PubMed Web of Science ®Google Scholar
• Khan K, Xu S, Nihtyanova S, et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis. 2012;71(7):1235–1242. doi: 10.1136/annrheumdis-2011-200955
   PubMed Web of Science ®Google Scholar
• Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford). 2013;52(1):155–160. doi: 10.1093/rheumatology/kes289
   PubMed Web of Science ®Google Scholar
• Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–1815. doi: 10.1136/ard.2009.114264
   PubMed Web of Science ®Google Scholar
• Groseanu L, Petrescu S, Balanescu A, et al. Do we have good activity indices in systemic sclerosis? Curr Rheumatol Rev. 2022;18(1):39–47. doi: 10.2174/1573397117666210913102759
   PubMed Web of Science ®Google Scholar
• Jaeger VK, Wirz EG, Allanore Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLOS ONE. 2016;11(10):e0163894. doi: 10.1371/journal.pone.0163894
   PubMed Web of Science ®Google Scholar
• Hugle T, Schuetz P, Daikeler T, et al. Late-onset systemic sclerosis–a systematic survey of the EULAR scleroderma trials and research group database. Rheumatology (Oxford). 2011;50(1):161–165. doi: 10.1093/rheumatology/keq321
   PubMed Web of Science ®Google Scholar
• Czirjak L, Kumanovics G, Varju C, et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis. 2008;67(1):59–63. doi: 10.1136/ard.2006.066340
   PubMed Web of Science ®Google Scholar
• Fransen J, Popa-Diaconu D, Hesselstrand R, et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis. 2011;70(10):1788–1792. doi: 10.1136/ard.2010.144360
   PubMed Web of Science ®Google Scholar
• Gigante A, Hoffmann-Vold AM, Fegatelli DA, et al. Estimated glomerular filtration rate is a marker of mortality in the European scleroderma trials and research group (EUSTAR) database. Rheumatology. 2022;61(1):213–222. doi: 10.1093/rheumatology/keab302
   Web of Science ®Google Scholar
• Becker M, Graf N, Sauter R, et al. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European scleroderma trials and research (EUSTAR) analysis. Ann Rheum Dis. 2019;78(9):1242–1248. doi: 10.1136/annrheumdis-2019-215145
   PubMed Web of Science ®Google Scholar
• Ross L, Nikpour M. Composite measures to assess disease damage, disease severity and treatment response in systemic sclerosis clinical trials. Curr Opin Rheumatol. 2023;35(6):334–340. doi: 10.1097/BOR.0000000000000971
   PubMed Web of Science ®Google Scholar
• Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clin Exp Rheumatol. 2003;21(3 Suppl 29):S39–41.
   PubMed Web of Science ®Google Scholar
• Valentini G, Iudici M, Walker UA, et al. The European scleroderma trials and research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis. 2017;76(1):270–276. doi: 10.1136/annrheumdis-2016-209768
   PubMed Web of Science ®Google Scholar
• Minier T, Nagy Z, Balint Z, et al. Construct validity evaluation of the European scleroderma study group activity index, and investigation of possible new disease activity markers in systemic sclerosis. Rheumatology (Oxford). 2010;49(6):1133–1145. doi: 10.1093/rheumatology/keq022
   PubMed Web of Science ®Google Scholar
• Khanna D, Distler O, Avouac J, et al. Measures of response in clinical trials of systemic sclerosis: the combined response index for systemic sclerosis (CRISS) and outcome measures in pulmonary arterial hypertension related to systemic sclerosis (EPOSS). J Rheumatol. 2009;36(10):2356–2361. doi: 10.3899/jrheum.090372
   PubMed Web of Science ®Google Scholar
• Ross L, Hansen D, Proudman S, et al. OP0235 developement and preliminary validation of the novel scleroderma clinical trials consortium activity index. Annals Rheu Dise. 2023;82(Suppl 1): 155–156. doi: 10.1136/annrheumdis-2023-eular.1239
   Google Scholar
• Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1339. doi: 10.1136/annrheumdis-2016-209909
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold AM, Allanore Y, Alves M, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021;80(2):219–227. doi: 10.1136/annrheumdis-2020-217455
   PubMed Web of Science ®Google Scholar
• Guler S, Sarbu AC, Stalder O, et al. Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysis. Thorax. 2023;78(12):1188–1196. doi: 10.1136/thorax-2023-220541
   PubMed Web of Science ®Google Scholar
• Volkmann ER, Tashkin DP, Sim M, et al. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Ann Rheum Dis. 2019;78(1):122–130. doi: 10.1136/annrheumdis-2018-213708
   PubMed Web of Science ®Google Scholar
• Kreuter M, Del Galdo F, Miede C, et al. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis. Arthritis Res Ther. 2022;24(1):19. doi: 10.1186/s13075-021-02710-9
   PubMed Web of Science ®Google Scholar
• Volkmann ER, Tashkin DP, Roth MD, et al. Early radiographic progression of scleroderma: lung disease predicts long-term mortality. Chest. 2022;161(5):1310–1319. doi: 10.1016/j.chest.2021.11.033
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold AM, Maher TM, Philpot EE, et al. Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. ERJ Open Res. 2021;7(1):00235–2020. doi: 10.1183/23120541.00235-2020
   PubMedGoogle Scholar
• Rahaghi FF, Hsu VM, Kaner RJ, et al. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. Resp Res. 2023;24(1):6. doi: 10.1186/s12931-022-02292-3
   PubMed Web of Science ®Google Scholar
• Khanna D, Lescoat A, Roofeh D, et al. Systemic sclerosis-associated interstitial lung disease: how to incorporate two food and drug administration-approved therapies in clinical practice. Arthritis Rheumatol. 2022;74(1):13–27. doi: 10.1002/art.41933
   PubMed Web of Science ®Google Scholar
• Allanore Y, Vonk MC, Distler O, et al. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON. Ann Rheum Dis. 2022;81(12):1722–1729. doi: 10.1136/ard-2022-222564
   PubMed Web of Science ®Google Scholar
• Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSscinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630–2640. doi: 10.1016/S0140-6736(16)00232-4
   PubMed Web of Science ®Google Scholar
• Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963–974. doi: 10.1016/S2213-2600(20)30318-0
   PubMed Web of Science ®Google Scholar
• Khanna D, Lin CJF, Furst DE, et al. Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a phase 3 randomized controlled trial. Am J Respir Crit Care Med. 2022;205(6):674–684. doi: 10.1164/rccm.202103-0714OC
   PubMed Web of Science ®Google Scholar
• Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2021;3(7):e489–e497. doi: 10.1016/S2665-9913(21)00107-7
   PubMedGoogle Scholar
• Mankikian J, Caille A, Reynaud-Gaubert M, et al. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur Respir J. 2023;61(6):2202071. doi: 10.1183/13993003.02071-2022
   PubMed Web of Science ®Google Scholar
• Elhai M, Boubaya M, Distler O, et al. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019;78(7):979–987. doi: 10.1136/annrheumdis-2018-214816
   PubMed Web of Science ®Google Scholar
• Sircar G, Goswami RP, Sircar D, et al. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford). 2018;57(12):2106–2113. doi: 10.1093/rheumatology/key213
   PubMed Web of Science ®Google Scholar
• Fraticelli P, Fischetti C, Salaffi F, et al. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study. Clin Exp Rheumatol. 2018;36 Suppl 113(4):142–145.
   PubMed Web of Science ®Google Scholar
• Tyndall A. Hematopoietic stem cell transplantation for systemic sclerosis: review of Current status. BioDrugs. 2019;33(4):401–409. doi: 10.1007/s40259-019-00364-3
   PubMed Web of Science ®Google Scholar
• Sehgal S, Pennington KM, Zhao H, et al. Lung transplantation in systemic sclerosis: a practice survey of United States lung transplant centers. Transplant Direct. 2021;7(10):e757. doi: 10.1097/TXD.0000000000001209
   PubMed Web of Science ®Google Scholar
• Campochiaro C, De Luca G, Lazzaroni MG, et al. Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study. RMD Open. 2023;9(1):e002850. doi: 10.1136/rmdopen-2022-002850
   PubMed Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–2528. doi: 10.1056/NEJMoa1903076
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold AM, Brunborg C, Airo P, et al. Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from European scleroderma trials and research. Chest. 2023;163(3):586–598. doi: 10.1016/j.chest.2022.09.044
   PubMed Web of Science ®Google Scholar
• Xanthouli P, Echampati I, Lorenz HM, et al. Respiratory involvement in connective tissue diseases. Eur J Internal Med. 2024;120:11–16. doi: 10.1016/j.ejim.2023.09.016
   PubMed Web of Science ®Google Scholar
• Mihai C, Antic M, Dobrota R, et al. Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. Ann Rheum Dis. 2018;77(1):128–132. doi: 10.1136/annrheumdis-2017-211480
   PubMed Web of Science ®Google Scholar
• Carreira PE, Carmona L, Joven BE, et al. Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis. Clin Exp Rheumatol. 2017;35 Suppl 106(4):114–121.
   PubMed Web of Science ®Google Scholar
• Colalillo A, Hoffmann-Vold AM, Pellicano C, et al. The role of TAPSE/sPAP ratio in predicting pulmonary hypertension and mortality in the systemic sclerosis EUSTAR cohort. Autoimmun Rev. 2023;22(4):103290. doi: 10.1016/j.autrev.2023.103290
   PubMed Web of Science ®Google Scholar
• Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL identifying systemic sclerosis as a unique phenotype. Chest. 2010;138(6):1383–1394. doi: 10.1378/chest.10-0260
   PubMed Web of Science ®Google Scholar
• Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–3731. doi: 10.1093/eurheartj/ehac237
   PubMed Web of Science ®Google Scholar
• Khanna D, Zhao C, Saggar R, et al. Long-term outcomes in patients with connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era: meta-analyses of randomized, controlled trials and observational registries. Arthritis Rheumatol. 2021;73(5):837–847. doi: 10.1002/art.41669
   PubMed Web of Science ®Google Scholar
• Xanthouli P, Jordan S, Milde N, et al. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. Ann Rheumatic Dis. 2020;79(3):370–378. doi: 10.1136/annrheumdis-2019-216476
   PubMed Web of Science ®Google Scholar
• Kuwana M, Blair C, Takahashi T. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis (vol 79, pg 626, 2020). Ann Rheum Dis. 2020;79(5):626–634. doi: 10.1136/annrheumdis-2019-216274
   PubMed Web of Science ®Google Scholar
• Chauvelot L, Gamondes D, Berthiller J, et al. Hemodynamic response to treatment and outcomes in pulmonary hypertension associated with interstitial lung disease versus pulmonary arterial hypertension in systemic sclerosis: data from a study identifying prognostic factors in pulmonary hypertension associated with interstitial lung disease. Arthritis Rheumatol. 2021;73(2):295–304. doi: 10.1002/art.41512
   PubMed Web of Science ®Google Scholar
• Wirz EG, Jaeger VK, Allanore Y, et al. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis. 2016;75(7):1285–1292. doi: 10.1136/annrheumdis-2015-207271
   PubMed Web of Science ®Google Scholar
• Herrick AL, Peytrignet S, Lunt M, et al. Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European scleroderma observational study. Ann Rheum Dis. 2018;77(4):563–570. doi: 10.1136/annrheumdis-2017-211912
   PubMed Web of Science ®Google Scholar
• Hughes M, Herrick AL. Systemic sclerosis. Br J Hosp Med. 2019;80(9):530–536. doi: 10.12968/hmed.2019.80.9.530
   PubMed Web of Science ®Google Scholar
• Namas R, Tashkin DP, Furst DE, et al. Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials. Arthritis Care Res (Hoboken). 2018;70(3):439–444. doi: 10.1002/acr.23282
   PubMed Web of Science ®Google Scholar
• Shouval R, Furie N, Raanani P, et al. Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2018;24(5):937–944. doi: 10.1016/j.bbmt.2018.01.020
   PubMed Web of Science ®Google Scholar
• Kuster S, Jordan S, Elhai M, et al. Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. RMD Open. 2022;8(2):e002477. doi: 10.1136/rmdopen-2022-002477
   PubMed Web of Science ®Google Scholar
• Davuluri S, Lood C, Chung L. Calcinosis in systemic sclerosis. Curr Opin Rheumatol. 2022;34(6):319–327. doi: 10.1097/BOR.0000000000000896
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Krieg T, Guillevin L, et al. Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO registry. Ann Rheum Dis. 2016;75(10):1770–1776. doi: 10.1136/annrheumdis-2015-208121
   PubMed Web of Science ®Google Scholar
• Brand M, Hollaender R, Rosenberg D, et al. An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database. Clin Exp Rheumatol. 2015;33(4 Suppl 91):S47–54.
   PubMed Web of Science ®Google Scholar
• Manfredi A, Sebastiani M, Carraro V, et al. Prediction risk chart for scleroderma digital ulcers: a composite predictive model based on capillaroscopic, demographic and clinico-serological parameters. Clin Hemorheol Micro. 2015;59(2):133–143. doi: 10.3233/CH-141809
   PubMed Web of Science ®Google Scholar
• Hughes M, Bruni C, Ruaro B, et al. Digital ulcers in systemic sclerosis. Presse Med. 2021;50(1):104064. doi: 10.1016/j.lpm.2021.104064
   PubMed Web of Science ®Google Scholar
• Zanatta E, Famoso G, Boscain F, et al. Nailfold avascular score and coronary microvascular dysfunction in systemic sclerosis: a newsworthy association. Autoimmun Rev. 2019;18(2):177–183. doi: 10.1016/j.autrev.2018.09.002
   PubMed Web of Science ®Google Scholar
• Avouac J, Lepri G, Smith V, et al. Sequential nailfold videocapillaroscopy examinations have responsiveness to detect organ progression in systemic sclerosis. Semin Arthritis Rheum. 2017;47(1):86–94. doi: 10.1016/j.semarthrit.2017.02.006
   PubMed Web of Science ®Google Scholar
• Mihai C, Landewe R, van der Heijde D, et al. Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis. 2016;75(4):681–686. doi: 10.1136/annrheumdis-2014-205897
   PubMed Web of Science ®Google Scholar
• Castellví I, Eguiluz S, Escudero-Contreras A, et al. LAUDES study: impact of digital ulcers on hand functional limitation, work productivity and daily activities, in systemic sclerosis patients. Rheumatol Int. 2019;39(11):1875–1882. doi: 10.1007/s00296-019-04436-z
   PubMed Web of Science ®Google Scholar
• Roustit M, Blaise S, Allanore Y, et al. Phosphodiesterase-5 inhibitors for the treatment of secondary raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013;72(10):1696–1699. doi: 10.1136/annrheumdis-2012-202836
   PubMed Web of Science ®Google Scholar
• Tingey T, Shu J, Smuczek J, et al. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken). 2013;65(9):1460–1471. doi: 10.1002/acr.22018
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70(1):32–38. doi: 10.1136/ard.2010.130658
   PubMed Web of Science ®Google Scholar
• Ingegnoli F, Schioppo T, Allanore Y, et al. Practical suggestions on intravenous iloprost in raynaud’s phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus. Semin Arthritis Rheum. 2019;48(4):686–693. doi: 10.1016/j.semarthrit.2018.03.019
   PubMed Web of Science ®Google Scholar
• Jerjen R, Nikpour M, Krieg T, et al. Systemic sclerosis in adults. Part II: management and therapeutics. J Am Acad Dermatol. 2022;87(5):957–978. doi: 10.1016/j.jaad.2021.10.066
   PubMed Web of Science ®Google Scholar
• Garaiman A, Steigmiller K, Gebhard C, et al. Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model. Rheumatology (Oxford). 2023;62(SI):SI91–SI100. doi: 10.1093/rheumatology/keac405
   PubMedGoogle Scholar
• Blagojevic J, Abignano G, Avouac J, et al. Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study. Clin Rheumatol. 2020;39(1):27–36. doi: 10.1007/s10067-019-04564-8
   PubMed Web of Science ®Google Scholar
• Negrini S, Magnani O, Matucci-Cerinic M, et al. Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. Clin Exp Med. 2019;19(3):357–366. doi: 10.1007/s10238-019-00553-y
   PubMed Web of Science ®Google Scholar
• Ross L, Costello B, Brown Z, et al. Myocardial fibrosis and arrhythmic burden in systemic sclerosis. Rheumatology (Oxford). 2022;61(11):4497–4502. doi: 10.1093/rheumatology/keac065
   PubMed Web of Science ®Google Scholar
• Kurmann RD, El-Am EA, Radwan YA, et al. Increased risk of valvular heart disease in systemic sclerosis: an underrecognized cardiac complication. J Rheumatol. 2021;48(7):1047–1052. doi: 10.3899/jrheum.201005
   PubMed Web of Science ®Google Scholar
• Moysidou GS, Dara A, Arvanitaki A, et al. Understanding and managing cardiac involvement in systemic sclerosis. Expert Rev Clin Immunol. 2023;19(3):293–304. doi: 10.1080/1744666X.2023.2171988
   PubMed Web of Science ®Google Scholar
• Bruni C, Buch MH, Djokovic A, et al. Consensus on the assessment of systemic sclerosis-associated primary heart involvement: world scleroderma foundation/heart failure association guidance on screening, diagnosis, and follow-up assessment. J Scleroderma Relat Disord. 2023;8(3):169–182. doi: 10.1177/23971983231163413
   PubMed Web of Science ®Google Scholar
• Basyal B, Ullah W, Derk CT. Pericardial effusions and cardiac tamponade in hospitalized systemic sclerosis patients: analysis of the national inpatient sample. BMC Rheumatol. 2023;7(1). doi: 10.1186/s41927-023-00360-9
   PubMedGoogle Scholar
• Ungprasert P, Charoenpong P, Ratanasrimetha P, et al. Risk of coronary artery disease in patients with systemic sclerosis: a systematic review and meta-analysis. Clin Rheumatol. 2014;33(8):1099–1104. doi: 10.1007/s10067-014-2681-4
   PubMed Web of Science ®Google Scholar
• Meiszterics Z, Timar O, Gaszner B, et al. Early morphologic and functional changes of atherosclerosis in systemic sclerosis-a systematic review and meta-analysis. Rheumatology (Oxford). 2016;55(12):2119–2130. doi: 10.1093/rheumatology/kew236
   PubMed Web of Science ®Google Scholar
• De Luca G, Bombace S, Monti L. Heart involvement in systemic sclerosis: the role of magnetic resonance imaging. Clin Rev Allergy Immunol. 2023;64(3):343–357. doi: 10.1007/s12016-022-08923-3
   PubMed Web of Science ®Google Scholar
• Gotschy A, Jordan S, Stoeck CT, et al. Diffuse myocardial fibrosis precedes subclinical functional myocardial impairment and provides prognostic information in systemic sclerosis. Eur Heart J Cardiovasc Imaging. 2023;24(3):373–382. doi: 10.1093/ehjci/jeac094
   PubMed Web of Science ®Google Scholar
• Panopoulos S, Mavrogeni S, Vlachopoulos C, et al. Cardiac magnetic resonance imaging before and after therapeutic interventions for systemic sclerosis-associated myocarditis. Rheumatology (Oxford). 2023;62(4):1535–1542. doi: 10.1093/rheumatology/keac504
   PubMed Web of Science ®Google Scholar
• Dimitroulas T, Giannakoulas G, Karvounis H, et al. Micro- and macrovascular treatment targets in scleroderma heart disease. Curr Pharm Des. 2014;20(4):536–544. doi: 10.2174/13816128113199990555
   PubMed Web of Science ®Google Scholar
• Valentini G, Huscher D, Riccardi A, et al. Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. Ann Rheum Dis. 2019;78(11):1576–1582. doi: 10.1136/annrheumdis-2019-215486
   PubMed Web of Science ®Google Scholar
• Allanore Y, Meune C, Vonk MC, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR scleroderma trial and research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis. 2010;69(1):218–221. doi: 10.1136/ard.2008.103382
   PubMed Web of Science ®Google Scholar
• De Luca G, Matucci-Cerinic M, Mavrogeni SI. Diagnosis and management of primary heart involvement in systemic sclerosis. Curr Opin Rheumatol. 2024;36(1):76–93. doi: 10.1097/BOR.0000000000000990
   PubMed Web of Science ®Google Scholar
• Pagkopoulou E, Arvanitaki A, Daoussis D, et al. Comorbidity burden in systemic sclerosis: beyond disease-specific complications. Rheumatol Int. 2019;39(9):1507–1517. doi: 10.1007/s00296-019-04371-z
   PubMed Web of Science ®Google Scholar
• Szamosi S, Szekanecz Z, Szucs G. Gastrointestinal manifestations in Hungarian scleroderma patients. Rheumatol Int. 2006;26(12):1120–1124. doi: 10.1007/s00296-006-0146-z
   PubMed Web of Science ®Google Scholar
• Volkmann ER, McMahan Z. Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment. Curr Opin Rheumatol. 2022;34(6):328–336. doi: 10.1097/BOR.0000000000000899
   PubMed Web of Science ®Google Scholar
• Ghrenassia E, Avouac J, Khanna D, et al. Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J Rheumatol. 2014;41(1):99–105. doi: 10.3899/jrheum.130386
   PubMed Web of Science ®Google Scholar
• Richard N, Hudson M, Wang M, et al. Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. Rheumatology (Oxford). 2019;58(4):636–644. doi: 10.1093/rheumatology/key350
   PubMed Web of Science ®Google Scholar
• Dein E, Kuo PL, Hong YS, et al. Evaluation of risk factors for pseudo-obstruction in systemic sclerosis. Semin Arthritis Rheum. 2019;49(3):405–410. doi: 10.1016/j.semarthrit.2019.05.005
   PubMed Web of Science ®Google Scholar
• Gonzalez Z, McCallum R. Small bowel dysmotility, pseudo obstruction, and functional correlation with histopathology: lessons learned. Curr Gastroenterol Rep. 2020;22(3):14. doi: 10.1007/s11894-020-0748-8
   PubMedGoogle Scholar
• Cheah JX, Perin J, Volkmann ER, et al. Slow colonic transit in systemic sclerosis: an objective assessment of risk factors and clinical phenotype. Arthritis Care Res (Hoboken). 2023;75(2):289–298. doi: 10.1002/acr.24767
   PubMed Web of Science ®Google Scholar
• Hughes M, Heal C, Siegert E, et al. Significant weight loss in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database. Ann Rheum Dis. 2020;79(8):1123–1125. doi: 10.1136/annrheumdis-2020-217035
   PubMed Web of Science ®Google Scholar
• Rosato E, Gigante A, Colalillo A, et al. GLIM-diagnosed malnutrition predicts mortality and risk of hospitalization in systemic sclerosis: a retrospective study. Eur J Internal Med. 2023;117:103–110. doi: 10.1016/j.ejim.2023.07.017
   PubMed Web of Science ®Google Scholar
• Volkmann ER, McMahan ZH, Smith V, et al. Risk of malnutrition in patients with systemic sclerosis-associated interstitial lung disease treated with nintedanib in the randomized, placebo-controlled SENSCIS trial. Arthrit Care Res. 2023;75(12):2501–2507. doi: 10.1002/acr.25176
   Web of Science ®Google Scholar
• Abignano G, Blagojevic J, Bissell LA, et al. European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. Rheumatology (Oxford). 2019;58(2):254–259. doi: 10.1093/rheumatology/key271
   PubMed Web of Science ®Google Scholar
• Foocharoen C, Chunlertrith K, Mairiang P, et al. Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial. Rheumatology (Oxford). 2017;56(2):214–222. doi: 10.1093/rheumatology/kew216
   PubMed Web of Science ®Google Scholar
• Low AHL, Teng GG, Pettersson S, et al. A double-blind randomized placebo-controlled trial of probiotics in systemic sclerosis associated gastrointestinal disease. Semin Arthritis Rheum. 2019;49(3):411–419. doi: 10.1016/j.semarthrit.2019.05.006
   PubMed Web of Science ®Google Scholar
• Vigone B, Caronni M, Severino A, et al. Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Arthritis Res Ther. 2017;19(1):145. doi: 10.1186/s13075-017-1340-y
   PubMedGoogle Scholar
• Zhong C, Qu C, Wang B, et al. Probiotics for preventing and treating small intestinal bacterial overgrowth: a meta-analysis and systematic review of Current evidence. J Clin Gastroenterol. 2017;51(4):300–311. doi: 10.1097/MCG.0000000000000814
   PubMed Web of Science ®Google Scholar
• Pittman N, Rawn SM, Wang M, et al. Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review. Rheumatology (Oxford). 2018;57(10):1802–1811. doi: 10.1093/rheumatology/key175
   PubMed Web of Science ®Google Scholar
• Nguyen AD, Andreasson K, McMahan ZH, et al. Gastrointestinal tract involvement in systemic sclerosis: the roles of diet and the microbiome. Semin Arthritis Rheum. 2023;60:152185. doi: 10.1016/j.semarthrit.2023.152185
   PubMed Web of Science ®Google Scholar
• van Leeuwen NM, Boonstra M, Fretheim H, et al. Gastrointestinal symptom severity and progression in systemic sclerosis. Rheumatology (Oxford). 2022;61(10):4024–4034. doi: 10.1093/rheumatology/keac118
   PubMed Web of Science ®Google Scholar
• Hudson M, Ghossein C, Steen V. Scleroderma renal crisis. Presse Med. 2021;50(1):104063. doi: 10.1016/j.lpm.2021.104063
   PubMed Web of Science ®Google Scholar
• Forman CJ, Olson SW, Gordon SM, et al. Association of race and risk of future scleroderma renal crisis at systemic sclerosis diagnosis. Arthritis Care Res (Hoboken). 2023;75(4):801–807. doi: 10.1002/acr.24807
   PubMed Web of Science ®Google Scholar
• Kim H, Lefebvre F, Hoa S, et al. Mortality and morbidity in scleroderma renal crisis: a systematic literature review. J Scleroderma Relat Disord. 2021;6(1):21–36. doi: 10.1177/2397198320920422
   PubMed Web of Science ®Google Scholar
• Cole A, Ong VH, Denton CP. Renal disease and systemic sclerosis: an update on scleroderma renal crisis. Clin Rev Allergy Immunol. 2023;64(3):378–391. doi: 10.1007/s12016-022-08945-x
   PubMed Web of Science ®Google Scholar
• Farrukh L, Steen VD, Shapiro L, et al. Studying the role of C5-inhibition therapy in scleroderma renal crisis-induced thrombotic microangiopathy - a review of literature. Semin Arthritis Rheum. 2023;63:152256. doi: 10.1016/j.semarthrit.2023.152256
   PubMed Web of Science ®Google Scholar
• Lorand V, Czirjak L, Minier T. Musculoskeletal involvement in systemic sclerosis. Presse Med. 2014;43(10):e315–e328. doi: 10.1016/j.lpm.2014.03.027
   PubMed Web of Science ®Google Scholar
• Avouac J, Walker UA, Hachulla E, et al. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis. 2016;75(1):103–109. doi: 10.1136/annrheumdis-2014-205295
   PubMed Web of Science ®Google Scholar
• Balint Z, Farkas H, Farkas N, et al. A three-year follow-up study of the development of joint contractures in 131 patients with systemic sclerosis. Clin Exp Rheumatol. 2014;32(6 Suppl 86):S-68–74.
   Web of Science ®Google Scholar
• Nagy G, Minier T, Varju C, et al. The presence of small joint contractures is a risk factor for survival in 439 patients with systemic sclerosis. Clin Exp Rheumatol. 2017;35 Suppl 106(4):61–70.
   PubMed Web of Science ®Google Scholar
• Chaigne B, Leonard-Louis S, Mouthon L. Systemic sclerosis associated myopathy. Autoimmun Rev. 2023;22(2):103261. doi: 10.1016/j.autrev.2022.103261
   PubMed Web of Science ®Google Scholar
• Corallo C, Fioravanti A, Tenti S, et al. Sarcopenia in systemic sclerosis: the impact of nutritional, clinical, and laboratory features. Rheumatol Int. 2019;39(10):1767–1775. doi: 10.1007/s00296-019-04401-w
   PubMed Web of Science ®Google Scholar
• Kayser C, Victoria de Oliveira Martins L. Treatment of inflammatory arthritis in systemic sclerosis. Rheum Dis Clin North Am. 2023;49(2):337–343. doi: 10.1016/j.rdc.2023.01.008
   PubMed Web of Science ®Google Scholar
• Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010;12(2):R54. doi: 10.1186/ar2965
   PubMed Web of Science ®Google Scholar
• Chaigne B, Rodeia S, Benmostefa N, et al. Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: a comparative study in 52 patients. Autoimmun Rev. 2020;19(1):102431. doi: 10.1016/j.autrev.2019.102431
   PubMed Web of Science ®Google Scholar
• Parodis I, Girard-Guyonvarc’h C, Arnaud L, et al. EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. Ann Rheum Dis. 2023. doi: 10.1136/ard-2023-224416
   PubMed Web of Science ®Google Scholar
• Jaeger VK, Walker UA. Erectile dysfunction in systemic sclerosis. Curr Rheumatol Rep. 2016;18(8). doi: 10.1007/s11926-016-0597-5
   PubMed Web of Science ®Google Scholar
• Thombs BD, Taillefer SS, Hudson M, et al. Depression in patients with systemic sclerosis: a systematic review of the evidence. Arthritis Rheum. 2007;57(6):1089–1097. doi: 10.1002/art.22910
   PubMed Web of Science ®Google Scholar
• Olah C, Schwartz N, Denton C, et al. Cognitive dysfunction in autoimmune rheumatic diseases. Arthritis Res Ther. 2020;22(1):78. doi: 10.1186/s13075-020-02180-5
   PubMed Web of Science ®Google Scholar
• AlMehmadi BA, To FZ, Anderson MA, et al. Epidemiology and treatment of peripheral neuropathy in systemic sclerosis. J Rheumatol. 2021;48(12):1839–1849. doi: 10.3899/jrheum.201299
   PubMed Web of Science ®Google Scholar
• Clark KE, Etomi O, Ong VH. Systemic sclerosis in pregnancy. Obstet Med. 2020;13(3):105–111. doi: 10.1177/1753495X19878042
   PubMed Web of Science ®Google Scholar
• Nemeth A, Szamosi S, Horvath A, et al. Systemic sclerosis and pregnancy. A review of the current literature. Z Rheumatol. 2014;73(2):175–179. doi: 10.1007/s00393-013-1267-x
   PubMed Web of Science ®Google Scholar
• Lazzaroni MG, Cavazzana I, Colombo E, et al. Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening. J Rheumatol. 2017;44(5):639–647. doi: 10.3899/jrheum.160817
   PubMed Web of Science ®Google Scholar
• Szekanecz E, Szamosi S, Gergely L, et al. Incidence of lymphoma in systemic sclerosis: a retrospective analysis of 218 Hungarian patients with systemic sclerosis. Clin Rheumatol. 2008;27(9):1163–1166. doi: 10.1007/s10067-008-0925-x
   PubMed Web of Science ®Google Scholar
• Szekanecz E, Szamosi S, Horvath A, et al. Malignancies associated with systemic sclerosis. Autoimmun Rev. 2012;11(12):852–855. doi: 10.1016/j.autrev.2012.02.021
   PubMed Web of Science ®Google Scholar
• Pauling JD, Caetano J, Campochiaro C, et al. Patient-reported outcome instruments in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2020;5(2):90–102. doi: 10.1177/2397198319886496
   PubMed Web of Science ®Google Scholar
• Becker MO, Dobrota R, Garaiman A, et al. Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR systemic sclerosis impact of disease (ScleroID) questionnaire. Ann Rheum Dis. 2022;81(4):507–515. doi: 10.1136/annrheumdis-2021-220702
   PubMed Web of Science ®Google Scholar
• Nagy G, Dobrota R, Becker MO, et al. Characteristics of ScleroID highlighting musculoskeletal and internal organ implications in patients afflicted with systemic sclerosis. Arthritis Res Ther. 2023;25(1):84. doi: 10.1186/s13075-023-03063-1
   PubMed Web of Science ®Google Scholar
• Ferdowsi N, Huq M, Stevens W, et al. Development and validation of the scleroderma clinical trials consortium damage index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. Ann Rheum Dis. 2019;78(6):807–816. doi: 10.1136/annrheumdis-2018-214764
   PubMed Web of Science ®Google Scholar
• Jamart C, Levesque H, Thietart S, et al. Iloprost duration for digital ulcers in systemic sclerosis: French retrospective study at two centers and literature review. Front Med. 2022;9:878970. doi: 10.3389/fmed.2022.878970
   Web of Science ®Google Scholar
• Herrick AL, Philobos M. Pharmacological management of digital ulcers in systemic sclerosis - what is new? Expert Opin Pharmacother. 2023;24(10):1159–1170. doi: 10.1080/14656566.2023.2213434
   PubMed Web of Science ®Google Scholar
• Denton CP, Hachulla E, Riemekasten G, et al. Efficacy and safety of selexipag in adults with raynaud’s phenomenon secondary to systemic sclerosis: a randomized, placebo-controlled, phase II study. Arthritis Rheumatol. 2017;69(12):2370–2379. doi: 10.1002/art.40242
   PubMed Web of Science ®Google Scholar
• Del Papa N, Vitali C, Bilia S, et al. Selexipag may be effective in inducing digital ulcers healing in patients with systemic sclerosis. Clin Exp Rheumatol. 2020;38 Suppl 125(3):181–182.
   PubMed Web of Science ®Google Scholar
• Almaaitah S, Highland KB, Tonelli AR. Management of pulmonary arterial hypertension in patients with systemic sclerosis. Integr Blood Press Control. 2020;13:15–29. doi: 10.2147/IBPC.S232038
   PubMed Web of Science ®Google Scholar
• Castellví I, Simeón CP, Sarmiento M, et al. Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers. PLOS ONE. 2020;15(12):e0243651. doi: 10.1371/journal.pone.0243651
   PubMed Web of Science ®Google Scholar
• Zamanian RT, Badesch D, Chung L, et al. Safety and efficacy of B-Cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: a multicenter, double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2021;204(2):209–221. doi: 10.1164/rccm.202009-3481OC
   PubMed Web of Science ®Google Scholar
• Acharya N, Sharma SK, Mishra D, et al. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial. Rheumatol Int. 2020;40(5):703–710. doi: 10.1007/s00296-020-04565-w
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold AM, Distler O, Crestani B, et al. Recent advances in the management of systemic sclerosis-associated interstitial lung disease. Curr Opin Pulm Med. 2022;28(5):441–447. doi: 10.1097/MCP.0000000000000901
   PubMed Web of Science ®Google Scholar
• Amati F, Stainer A, Polelli V, et al. Efficacy of Pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis: a systematic review. Int J Mol Sci. 2023;24(9):7849. doi: 10.3390/ijms24097849
   PubMed Web of Science ®Google Scholar
• Raghu G, Montesi SB, Silver RM, et al. Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2023;209(2):137–152. doi: 10.1164/rccm.202306-1113ST
   Web of Science ®Google Scholar
• Khanna D, Caldron P, Martin RW, et al. Adipose-derived regenerative cell transplantation for the treatment of hand dysfunction in systemic sclerosis: a randomized clinical trial. Arthritis Rheumatol. 2022;74(8):1399–1408. doi: 10.1002/art.42133
   PubMed Web of Science ®Google Scholar
• Bergmann C, Muller F, Distler JHW, et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis. 2023;82(8):1117–1120. doi: 10.1136/ard-2023-223952
   PubMed Web of Science ®Google Scholar